ArticlemedRxiv : the preprint server for health sciences2025
CSF Proteomics and Machine Learning Reveal Distinct Stages Across the Alzheimer's Disease Continuum.
Saima Rathore, Eric B Dammer, Anantharaman Shantaraman, Fang Wu, Duc M Duong, Edward J Fox, Erik C B Johnson, James J Lah, Alzheimer’s Disease Neuroimaging Initiative, Nicholas T Seyfried and 1 more
Abstract readPreprint
In one paragraphArticle in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Saima RathoreDepartment of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0003-4752-2298 Anantharaman ShantaramanDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0003-1384-941X Fang WuDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Duc M DuongDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Edward J FoxDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.
Erik C B JohnsonDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
James J LahDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Alzheimer’s Disease Neuroimaging Initiative
Allan I LeveyDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MThe Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Amy D Rodriguez · 2020 to 2026
$29.0MSupplement to AMP-AD Brain Proteomic Network Enhancement, Validation and Translation into CSF BiomarkersU01AG061357 · NIA · EMORY UNIVERSITY · PI LEVEY, ALLAN I, SEYFRIED, NICHOLAS THOMAS · 2018 to 2022
$9.1MVCID CWOW: Identifying Novel Targets to Treat Cerebral Amyloid AngiopathyRF1NS139948 · NINDS · JACKSON LABORATORY · PI HOWELL, GARETH R, SEYFRIED, NICHOLAS THOMAS · 2024 to 2024
$5.9MNeuron and microglia-specific proteomic signatures of ERK mediated mechanisms of Alzheimer’s diseaseR01AG075820 · NIA · YALE UNIVERSITY · PI RANGARAJU, SRIKANT, SEYFRIED, NICHOLAS THOMAS · 2021 to 2025
$5.1MGlycoproteomics and the Glycosylation Code of the Brain in Asymptomatic and Symptomatic Alzheimer’s DiseaseRF1AG062181 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CUMMINGS, RICHARD D, SEYFRIED, NICHOLAS THOMAS · 2018 to 2018
$4.1MNIA NIH HHS P30 AG066511NIA NIH HHS R01 AG075820NIA NIH HHS RF1 AG062181NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG061357NINDS NIH HHS RF1 NS139948
6 · The paper itselfAbstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by heterogeneous pathophysiological changes that begin years before symptoms emerge. Existing biomarkers like Aβ and pTau capture only fragments of this complexity, limiting diagnosis and therapeutic development. Leveraging high-resolution cerebrospinal fluid (CSF) proteomics, quantifying 2,492 proteins using tandem-mass-tag mass spectrometry (TMT-MS), in 1,104 ADNI participants, we identified pathways reflecting AD pathogenesis and stage-specific molecular events
Identifiers
PMID41292640
PMCPMC12642759
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390